Search tool

In December 2006, after examining the available information collected on BZP (1-benzylpiperazine), the EMCDDA and Europol decided to launch a procedure for the production of a Joint Report. Pursuant to the findings...

The report outlines the results of the implementation of the Council Decision in 2005 and describes some issues arising from the initial experiences. In 2005, 14 new psychoactive substances were officially notified...

The risk-assessment reports on the synthetic drugs 2C-I; 2C-T-2 and 2C-T-7 were submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The reports were drawn up at...

The risk-assessment report on the synthetic drug TMA-2 was submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The report was drawn up at a meeting in...

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in...

Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious...

Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing...

This publication was drawn up by the steering group created by the EMCDDA's Scientific Committee in November 1998 to establish guidelines to assess the risks of all new synthetic drugs identified under...

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange...